In vivo efficacy of platelet-delivered, high specific activity factor VIII variants - Wikidata - awgldk - TriplyDB

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

http://www.wikidata.org/entity/Q33695763

about

MicroRNAs in platelet production and activation Assessment of Venous Thrombosis in Animal Models The gene therapy journey for hemophilia: are we there yet?The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.Gene therapy for hemophilia Lessons Learned from Animal Models of Inherited Bleeding Disorders.The disulfide isomerase ERp57 is required for fibrin deposition in vivo.Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.Role of bone marrow transplantation for correcting hemophilia A in mice.α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity Engineering Factor Viii for Hemophilia Gene Therapy.Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice.Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Factor VIII inhibitors: a 50-year perspective.Gene therapy for haemophilia: a long and winding road.Blood Clotting Factor VIII: From Evolution to Therapy.Obstacles and future of gene therapy for hemophilia.Platelet-delivered therapeutics.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Targeting expression to megakaryocytes and platelets by lineage-specific lentiviral vectors.Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Platelet-Targeted Gene Therapy for Hemophilia.Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

P2860

Q24622537-E8C25FD2-E31E-4D97-A827-A36B69BC5501 Q26774967-90A6953D-FC39-44B3-94E9-68F30DBC9B6A Q26823818-2F29CB52-51B4-4A27-ADCF-6A43EA40CB8C Q27332350-00033A88-4C06-4362-B326-25F03CCD757E Q28081911-4DF31098-550E-4869-A6C3-A741A1488A7D Q30409863-A62BB0C8-842D-4071-B769-7B655AC5C265 Q35231637-80D102D8-7A6F-412B-8E2C-4F1242E07EAC Q35306206-2D0CF087-E38D-4426-849D-23B7DB4E2314 Q36015228-69663D31-629E-4692-8B6C-61CD51CE2023 Q36548363-A943836B-06AE-443C-AD84-837DF616041A Q36675079-DE84CFB3-1008-4FFB-8846-DD64217C9E82 Q36737263-8E22BDD7-B811-44DE-A777-DA2D01764FE5 Q36873312-6D27FDAC-2328-45DC-923C-A62A76E46584 Q37292357-D7E1B84D-8EE0-4D80-8ACC-730BDF423453 Q37366619-61C45DF6-5E17-4F32-A626-0D4E7ED9B735 Q37489033-B45D8663-3CDC-47B4-B03C-807FC035F2D4 Q37876956-359136A1-6C3C-4D8D-9134-B92708F7A483 Q37903924-6CFF4CAF-5047-4796-B676-1F1B3173AF49 Q38118763-257F7A09-3F03-4AAB-9C64-62247545B755 Q38529941-ADE15324-0298-4D6C-A359-438EC1FCF58D Q38543281-9938A081-B41F-4334-B515-CD88D57E759B Q38803022-A4BC7461-56B5-40B0-A3DB-7A99C1535C69 Q40435211-EFA8E2EE-9C83-462C-8B31-ED877161253E Q42209182-AC1916F5-9EB7-4F1C-B5A4-36F2D7EF76C3 Q42384645-23324E61-A8C5-494F-A276-9C4C5167AFD7 Q45857189-BFD1463F-05CE-401E-9F53-39D930A77CE0 Q54975244-45985A05-35BE-42D2-A37D-81B950EF48E3 Q55013009-5A194AD5-CF35-44C6-8FAD-E93F6B7F527F

P2860

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

http://www.wikidata.org/entity/Q33695763

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@ast

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@en

type

label

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@ast

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@en

prefLabel

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@ast

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@en

P1433

Q33695763-C64FD4AD-D384-4D64-8220-3189919B9560

P1476

Q33695763-CCD2A702-8B08-4C19-AB12-EAA6395BE173

P2093

Q33695763-07774FE7-2B50-4D12-A5FE-F6D67028A3F3

Q33695763-157467DA-0F30-4D09-8833-5357FFBB1AEE

Q33695763-1D335368-D0CD-4C08-B4E9-26E42B97EAA4

Q33695763-26EA97AB-B78E-4C83-9C75-2AD830E3DA21

Q33695763-31496E2B-548B-4B2F-A9EB-B54AEEB72EF3

Q33695763-3BC044C5-541E-4C5E-88E1-3C01025BB667

Q33695763-70FEA7E8-AE4F-4914-B1FA-1BA7B267CB3E

Q33695763-793BD340-10F5-4519-98DD-8C1B2171DE31

Q33695763-944622BB-EDFE-4BDB-A088-1BE36646CA11

Q33695763-A7C207EA-F946-4C18-8530-9FE33245F02C

P2860

Q33695763-0DB14508-6F43-4F82-B48B-D7DB207CE0CA

Q33695763-10740C2E-E0F6-4386-AFAA-3E662E27AAFF

Q33695763-13706DB7-C903-4812-80BB-FC935DE061CB

Q33695763-144EE6FE-1C6C-49BE-9497-553669FA7E22

Q33695763-235D96A7-276A-43AD-9D10-2BC146BF96A3

Q33695763-276B3107-172C-489A-A752-7561AE87D04F

Q33695763-27AD9659-E258-4126-8763-376E23400595

Q33695763-2F321B18-08D3-4C7D-9486-C906C692B6EE

Q33695763-397035EB-75EB-4C8D-8136-9C16B896919E

Q33695763-3F0E5481-F468-4DB3-8DF5-0481B3C8CFC4

P304

Q33695763-21FCABE9-AC60-4DF4-A955-BB587F99BA7C

P31

Q33695763-BB2AA0EF-8CF3-4947-83B0-4D5FA0154F8F

P356

Q33695763-21525410-71CA-469C-94CD-E179CB4ADFDD

P407

Q33695763-BFC732E4-407D-407D-90BC-9B91FE505A26

P433

Q33695763-6939B224-407D-49F9-9A72-1A91A28412C1

P478

Q33695763-6CA7D98E-E24F-497E-BE66-D980650B07F5

P50

Q33695763-1262763F-D8B4-4909-8449-F76B654935D0

P577

Q33695763-35CBC68A-C44F-4757-BED9-0A7DA89ACE50

P5875

Q33695763-13951FEC-6571-426C-A263-65E3B76BA496

P698

Q33695763-27CF05A7-B371-4D20-8771-85F60DE973AE

P932

Q33695763-42C2E29B-F1C3-4350-9758-E2986A27148E

P356

BLOOD-2010-06-293308

P1433

P1476

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

@en

P2093

Cheng Wang

http://www.w3.org/2001/XMLSchema#string

Hongzhi Z Miao

http://www.w3.org/2001/XMLSchema#string

Jamie Gewirtz

http://www.w3.org/2001/XMLSchema#string

Jessica D Hirsch

http://www.w3.org/2001/XMLSchema#string

Li Zhai

http://www.w3.org/2001/XMLSchema#string

Michael A Thornton

http://www.w3.org/2001/XMLSchema#string

Mortimer Poncz

http://www.w3.org/2001/XMLSchema#string

Randal J Kaufman

http://www.w3.org/2001/XMLSchema#string

Rodney M Camire

http://www.w3.org/2001/XMLSchema#string

Steven W Pipe

http://www.w3.org/2001/XMLSchema#string

P2860

Human endothelial cells in culture and in vivo express on their surface all four components of the glycoprotein Ib/IX/V complex

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots

Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.

Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy.

New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.

Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors.

Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.

Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.

P304

6114-6122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-06-293308

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46306352

http://www.w3.org/2001/XMLSchema#string

P698

20852129

http://www.w3.org/2001/XMLSchema#string

P932

3031396

http://www.w3.org/2001/XMLSchema#string